Piramal Pharma Q1 FY27: Standalone PAT Rs 113 cr, Consolidated loss Rs 69 cr
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Smallcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q1 FY27 standalone revenue rose to Rs 1,124.95 cr from Rs 969.88 cr YoY, about 16 percent growth. Standalone PAT was flat at Rs 113.48 cr vs Rs 113.14 cr. EPS held at Rs 0.85. Consolidated revenue grew to Rs 2,269.92 cr from Rs 1,933.71 cr, about 17 percent. But consolidated PAT was a loss of Rs 69.39 cr, wider than Rs 37.56 cr loss a year ago. No exceptional items this quarter. Overseas subsidiaries drove the group loss.
Standalone steady, but group losses deepen as overseas subsidiaries drag profitability. Mixed signals for shareholders despite revenue growth.